drugset / Trial / NCT02951962

A Study to Investigate Pharmacokinetic Drug Interaction and Safety of Telmisartan/Amlodipine and Rosuvastatin

NCT02951962

Phase 1 Completed 60 enrolled Yuhan Corporation
Non-randomizedCrossoverOpen-labelTreatment

Summary

This is a phase 1, open label, two-cohort, single-sequence, crossover study

Timeline

Start
2016-08
Primary completion
2016-09
Completion
2016-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified 5 mg
Subject Rosuvastatin Small molecule 20 mg
Subject Telmisartan Other / unclassified 80 mg